Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 12/20 | 0.68 |
| ▸ | THRA | P10827 | 9/20 | 0.68 |
| ▸ | THRB | P10828 | 9/20 | 0.68 |
| ▸ | BBOX1 | O75936 | 1/20 | 0.68 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.68 |
| ▸ | ASPH | Q12797 | 1/20 | 0.68 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.68 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.68 |
| ▸ | EGLN2 | Q96KS0 | 6/20 | 0.65 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetic Acid SCHEMBL30394209 | 0.97 | EGLN1 (0.65) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL14672078 | 0.90 | EGLN1 (0.71) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL12955515 | 0.89 | EGLN1 (0.55) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL14672080 | 0.86 | EGLN1 (0.70) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL31267308 | 0.86 | EGLN1 (0.70) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL29046746 | 0.86 | EGLN1 (0.67) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL12955452 | 0.85 | EGLN1 (0.52) | EGLN1THRATHRBBBOX1SLC6A2 | |
| SCHEMBL2350847 | 0.85 | EGLN1 (0.63) | EGLN1THRATHRBBBOX1SLC6A2 | |
| Acetic Acid SCHEMBL28993798 | 0.84 | THRA (0.65) | EGLN1THRATHRBBBOX1SLC6A2 | |
| Acetic Acid SCHEMBL28993801 | 0.84 | EGLN1 (0.64) | EGLN1THRATHRBBBOX1SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | AKEBIA THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| CN-115838354-B | Thyroid hormone receptor beta agonist compound and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2025-05-13 | — | — | CN | disclosed |
| WO-2023135499-A1 | PROCESS FOR ROXADUSTAT USING NOVEL INTERMEDIATES | OPTIMUS DRUGS PVT LTD (IN) | 2023-07-20 | — | — | WO | disclosed |
| CN-115838354-A | Thyroid hormone receptor beta agonist compound and preparation method and application thereof | 中国科学院广州生物医药与健康研究院 | 2023-03-24 | — | — | CN | disclosed |
| EP-3003284-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | Fibrogen, Inc. (US) | 2016-04-13 | — | — | EP | disclosed |
| WO-2014197660-A1 | PHARMACEUTICAL FORMULATIONS OF A HIF HYDROXYLASE INHIBITOR | FIBROGEN, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12612367-B2 | Method for producing nitrogen-containing heteroarylcarboxamide acetic acid derivative | DIMT1, HIF1A, HIF1AN | EGLN1 912/4885THRA 788/4885THRB 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.